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PREFACE 
Cancer has been treated with chemotherapeutic drugs for the last fifty years. But the 
effectiveness of the treatment has not always been as expected. This has been explained by 
the lack of drug specificity and most importantly drug resistance as the majority of the cancer 
patients develop resistance against chemotherapy. Therefore, identification of patients with a 
high probability of responding to specific treatment, and hence, prevent the non-responding 
patients from ineffective treatment, would improve therapy significantly. Despite this obvious 
advantage, the number of studies designed specifically to explore the mechanism of drug 
resistance in vivo are surprisingly few compared to the high number of studies done in vitro as 
well as compared to clinical therapy studies in general. Biopsies obtained from primary breast 
cancers before chemotherapy treatment provides a unique opportunity to investigate in vivo 
mechanisms of chemoresistance. Insight into such mechanisms is expected to lead to 
improved diagnostication and therapy. Our present project is designed to find possible 
association between alterations in functional cascades and therapy resistance.
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ABBREVIATIONS 
aa   Amino acid 
ATM   Ataxia telangiectasia mutated 
CDK   Cyclin-dependent kinase 
CDKN1A  Cyclin-dependent kinase inhibitor 1A 
CHEK2  Checkpoint kinase 2 gene 
Chk2   Checkpoint kinase 2 protein  
dsDNA  Double stranded DNA 
ER   Estrogen receptor 
IHC   Immunohistochemistry 
INK   Inhibitor of kinase 
KIP   Kinase inhibitor protein 
LFL   Li-Fraumeni-like syndrome 
LFS   Li-Fraumeni syndrome 
LOH   Loss of heterozygosity 
Mdm2   Mouse double minute 2 homolog 
pRB   Retinoblastoma protein 
p53   The protein encoded by the TP53 gene 
SNP   Single nucleotide polymorphism 
TP53   Gene encoding p53 protein 
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DEFINITIONS 
Adjuvant
Adjuvant therapy refers to additional treatment, usually given after surgery where all 
detectable tumor has been removed aiming to eliminate micro-metastases. 
Apoptosis
Apoptosis or “programmed cell death” is defined as a mechanism of cellular suicide which 
occurs after sufficient cellular damage.  
 
Lumpectomy
Lumpectomy is surgery in which only the tumor and some surrounding tissue is removed. 
Mastectomy
Mastectomy means surgical removal of the entire diseased breast, in general due to breast 
cancer. 
 
Neo-adjuvant
Neo-adjuvant therapy refers to chemotherapy or endocrine treatment given to cancer patients 
prior to surgery. The general reason for neo-adjuvant therapy is to reduce the size of the tumor 
to facilitate limited surgery (so-called “lumpectomy”).  
 
Predictive factor 
Predictive factor defines sensitivity of a tumor to a distinct therapeutic agent. 
 
Prognostic factor 
Prognostic factor is a term denoting risk of disease relapse or death. Strictly speaking, it 
should be recorded among patients not undergoing adjuvant systemic therapy to avoid 
interference from therapy. 
Senescence
Cellular senescence is the phenomenon where normal cells lose the ability to divide, a form of 
permanent cell cycle arrest. 
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1 INTRODUCTION 
1.1 Cancer 
Cancer is a class of diseases or disorders characterized by uncontrolled cell growth 
and/or defects in critical control mechanisms (like growth arrest or ability to undergo 
apoptosis). Furthermore, cancer cells are characterized by their ability to spread, either by 
direct growth into adjacent tissue through invasion, or by implantation into distant sites by 
metastasis. The unregulated growth that characterizes cancer is caused by mutations in genes 
that encode proteins controlling cell homeostasis. 
Cancer-associated genes are divided into proto-oncogenes/oncogenes and tumor 
suppressor genes. Proto-oncogenes are genes encoding proteins which promote cell growth 
and mitosis, a process of cell division, and tumor suppressor genes encodes proteins that 
discourage cell growth, or temporarily halt cell division in order to allow DNA repair, induce 
apoptosis and/or senescence. Typically, a series of several mutations to these genes are 
required before a normal cell transforms into a cancer cell. Most simply defined proto-
oncogenes contribute to cancer by over expression or constitutive activation, whereas tumor 
suppressor genes contribute to cancer by a loss of function. Tumor suppressor genes code for 
anti-proliferation signals and proteins that suppress mitosis and cell growth. Generally, tumor 
suppressors are activated by cellular stress or DNA damage. The functions of such genes are 
to arrest the progression of cell cycle in order to carry out DNA repair, preventing mutations 
from being passed on to daughter cells. Most tumor suppressor genes are inactivated by 
mutations leading to absence of wild type proteins.  
1.1.1 Breast cancer 
Breast cancer is the most commonly occurring cancer among women, causing more 
deaths in the western world than any other cancer except for cancer of the lung (Greenlee, 
Murray et al. 2000; Jemal, Thomas et al. 2002). While breast cancer incidence is still 
increasing, mortality from breast cancer is decreasing in many western societies, probably due 
to combined effect of early detection and improvements in treatment (Peto, Boreham et al. 
2000; Balmain, Gray et al. 2003). The risk of getting breast cancer increases with age. For 
someone who lives to the age of 90, the chances of getting breast cancer has been estimated to 
be as high as 14% or one in seven during their lifetime. Men can also develop breast cancer 
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because the breast is composed of identical tissues in males and females. Male breast cancer 
incidence is less than 1% of all breast cancer cases (Agrawal, Ayantunde et al. 2007). 
The cause of breast cancer is complex and not fully understood. Germline genetic 
alterations of highly penetrant genes like the tumor suppressor genes BRCA1, BRCA2 and 
TP53 are suggested to explain only 5-10% of all breast cancer cases (Ford, Easton et al. 1995; 
Martin and Weber 2000). Thus, the majority of breast cancer cases is probably caused by life-
style factors, environmental (Buell 1973; Kaur 2000), and/or alterations in a variety of low-
penetrance breast cancer susceptibility genes (Martin and Weber 2000). The major differences 
in breast cancer incidence between ethnic groups and geographic areas in general are assumed 
to be due to life style/environmental factors, probably diet, smoking, high-alcohol 
consumption and not differences with respect to ethnic background. Evidence in favor of this 
view was provided when it was revealed that Japanese women immigrating to America over 
time adapted a breast cancer risk resembling white Americans (Buell 1973). 
 Low penetrance susceptibility genes are genes with specific sequence variants or 
polymorphisms that may be associated with an increased breast cancer risk (Weber and 
Nathanson 2000). Although each variant is only associated with a small increased risk for 
breast cancer, their common appearance may explain that their attributable risk in the 
population as a whole may be higher than that of so-called high penetrance genes. In families 
with several breast cancer cases in the absence of any known germ-line syndrome, interplay 
between low-penetrance genes and lifestyle factors may contribute to the higher risk for breast 
cancer (Balmain, Gray et al. 2003).  
 
1.1.2 Breast cancer treatment 
Today’s treatment of breast cancer includes a multimodal approach consisting mainly 
of surgery, combined to a variable degree with adjuvant chemotherapy, radiation therapy and 
hormone therapy depending on tumor and patient characteristics. Once diagnosed, most breast 
cancers are primarily treated by surgical removal of the tumor (lumpectomy) or the entire 
diseased breast (mastectomy) following adjuvant systemic therapy to reduce the risk of a 
relapse. While for most patients surgery is performed upfront to any additional therapy, use of 
primary, or so-called neo-adjuvant chemo- or endocrine therapy is increasingly used, in 
particular for larger tumors. 
Breast cancer evolves in the epithelial tissue in breast. As these cells proliferate under 
hormonal control, breast cancer may often be treated by endocrine therapy when the tumor 
cells have retained the estrogen receptor (ER) (2005). The exception is patients with a 
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particular low risk of relapse. Tamoxifen, an ER modulator that binds ER and obstructs 
estrogen from binding, is a general regime often given to premenopausal women. For 
postmenopausal women, aromatase inhibitors are the first-line therapy, either used alone or 
sequentially treatment with tamoxifen. Aromatase produces estrogen from androgens in 
various tissues. This reaction is the main source of estrogen after menopause (Lonning, 
Dowsett et al. 1990). 
Chemotherapy and/or radiation therapy may also be used before or after surgery. 
While some local relapses may be related to residual cancer tissue deposits, the key problem 
relates to development of distant micro-metastases. Radiation therapy, which only has a 
moderate effect on overall survival, is commonly prescribed for women who have undergone 
lumpectomy or mastectomy surgery with the purpose to reduce the risk that cancer will recur 
(Overgaard, Hansen et al. 1997). Radiation therapy eliminates the microscopic cancer cells 
that may remain near the area where the tumor was surgically removed. 
Adjuvant therapy has been found to reduce the risk of a relapse, with anthracycline-
based treatments most effective (2005).  
Combination of cytostatic and endocrine therapy may reduce the death rate by up to 
50%, compared to adjuvant therapy (2005). Thus patients with hormone-sensitive tumors are 
in general treated with endocrine therapy alone.  
Chemotherapy, in particular those forms in focus in this study, will be described in 
more detail in the following section. 
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1.2 Chemotherapy 
 Cancer has been treated with chemotherapeutic drugs for the last fifty years. With the 
exceptions of a few cancer forms, cure rates have not met the initial optimistic expectations. 
This is explained with lack of specificity and most importantly the development of drug 
resistance in tumor cells.  
Neo-adjuvant chemotherapy is used to reduce the size of a tumor prior to surgery and 
also to prevent development of micro-metastasis. Neo-adjuvant chemotherapy is being 
increasingly utilized in patients with locally advanced breast cancer and many centers are 
favoring treatment with cytotoxic agents and radiotherapy before surgery to “downstage” 
tumors, opening the possibility of limited surgery such as lumpectomy and thus to avoid 
mastectomy. Adjuvant chemotherapy is given after surgery to reduce the risk of recurrence 
and to eliminate micro-metastasis thereby preventing distant metastasis.  
There are several different chemotherapy regimens that may be used. The 
determination of the appropriate regimen depends on many factors including the primary 
characteristics of the tumor (size and histological grade), lymph node status, and the age and 
health of the patient. Thus, apart from the old patients, patients harboring lymph node 
metastases or patients without lymph node metastases but harboring other negative prognostic 
characteristics are in general treated with a combination of several drugs in general including 
an anthracycline. The general effect of chemotherapy treatment is believed to be that most 
anticancer drugs kill cells by inducing apoptosis in the malign cells (Kerr, Winterford et al. 
1994; Ellis, Smith et al. 1997). This is achieved through induction of several different 
intracellular pathways. Even though, it is well documented that anticancer drugs often kill 
cells by inducing apoptosis, it is still a problem to pinpoint the exact mechanisms as there are 
indicated that senescence may parallel apoptosis in response to stress (Schmitt, Fridman et al. 
2002). However, this is not completely understood. Study of the alterations in the components 
of the apoptotic pathways may yield information about the molecular pathways associated 
with chemotherapy response and resistance. There are very few studies that have investigated 
the biology of the neo-adjuvant chemotherapy in vivo and those that exist are limited in the 
number of time points. Mainly, most of these studies are done in paraffin embedded tissue, 
due to lack of availability of frozen tissue, at this limited to immunohistochemistry (IHC). 
However, numerous studies have tried to identify markers or variations in markers that are 
associated with response or resistance to treatment. 
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 The two classes of cytotoxic drugs that demonstrate most activity towards breast 
cancers are anthracyclines and taxanes.  
 
1.2.1 Epirubicin  
One of the most commonly used anthracycline, doxorubicin, is a natural compound 
produced by the Streptomyces species, whereas epirubicin, which is also widely used in the 
treatment of breast cancer, is synthetically produced.  
Similarity to other anthracyclines, epirubicin acts through binding DNA resulting in 
inhibition of topoisomerase II and fragmentation of DNA (Smith and Soues 1994), resulting 
in mechanisms that lead to cell death. Furthermore, anthracyclines can undergo reduction to 
generate free radicals that cause cell and DNA damage (Cummings, Anderson et al. 1991; 
Muller, Niethammer et al. 1998). Epirubicin is favored over doxorubicin as it appears to cause 
fewer side-effects, faster elimination and reduced toxicity (Bhutani, Kumar et al. 2002). 
 
1.2.2 Paclitaxel (Taxol)  
Taxol, a brand name of paclitaxel, is one of the most effective anticancer drugs used in 
the clinic to treat a variety of solid tumors. The first taxane, paclitaxel was initially extracted 
from the bark of the pacific yew Taxus brevifolia in the 1960`s. Since that time its use as an 
anti-cancer drug has become well established. 
 During cell division, taxanes interfere with the development of the microtubules 
needed for the cell duplication thus inhibiting the faster growing tumor cells (Parness and 
Horwitz 1981). Paclitaxel interferes with normal function of microtubule growth, and 
stabilizes their structure. This destroys the cell’s ability to use its cytoskeleton in a flexible 
manner. Specifically, paclitaxel binds to the ß-subunit of tubulin. Tubulin is the building 
block of microtubules, and the binding of paclitaxel locks these building blocks in place. The 
resulting microtubule-paclitaxel complex does not have the ability to disassemble (Jordan, 
Wendell et al. 1996), a requisite for microtubule dynamic function.  This adversely affects cell 
function because the shortening and lengthening of microtubules is necessary for their 
function as a mechanism to transport other cellular components. Especially in the M-phase of 
the cell cycle, when chromosomes are separated into daughter cells by dissembling of the 
microtubules they are attached to.  
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1.2.3 Resistance to chemotherapy 
The main obstacle to chemotherapy treatment is resistance to cytostatic regimes. 
Resistance to chemotherapy remains a major challenge in the treatment of breast cancer. 
Apart from applying effective treatment, to avoid patients having ineffective toxic treatment is 
a main goal in cancer therapy. 
As mentioned above, defective apoptosis is considered to be a central event in 
malignant tumors. The general effects of most chemotherapeutic drugs are in generally 
believed to require functioning apoptotic pathways to induce cell death, this could be one 
explanation of why also drug-naive tumors can be resistant. We know that alterations leading 
to disturbances in the apoptotic pathway results in drug resistance (Evan and Vousden 2001). 
However, at the present time there is no reliable means of predicting chemotherapy 
responsiveness. Biopsies obtained from breast cancers during neo-adjuvant chemotherapy 
provide a valuable opportunity to observe the pathways involved in cell death. The molecular 
characterization may provide an improved understanding of the mechanisms of 
chemoresistance and lead to new, targeted treatment strategies.
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1.3 The p53 signaling pathway network 
Cells respond to DNA damage by activating a DNA damage-response pathway that 
includes cell cycle arrest, transcriptional and posttranscriptional regulation of genes associated 
with repair and programmed cell death (Vogelstein, Lane et al. 2000). The pathway provides a 
mechanism for transmitting a signal from a sensor that recognizes the damage, through a 
transduction cascade, to a series of downstream effectors, which implement the appropriate 
response.  
The p53 signaling pathway is in “standby” mode under normal cellular conditions. 
Activation occurs in response to cellular stresses or damage, and several independent 
pathways of p53 activation have been identified (Vogelstein, Lane et al. 2000). Recent 
research has confirmed the existence of at least three independent pathways by which p53 
network can be activated. One pathway is indeed triggered by DNA damage, caused by drugs 
like anthracyclines and ionizing radiation. This activation of the network is dependent on two 
protein kinases, ATM (Ataxia Telangiectasia Mutated) and Chk2 (Checkpoint kinase 2) 
(described in detail below). The second pathway may be induced by ultraviolet light and 
protein kinase inhibitors. This pathway is distinguished from others because it is not 
dependent on intact ATM or Chk2. Instead, this pathway involves kinases called ATR (ataxia 
telangiectasia related kinases). The third pathway for activating p53 is triggered by aberrant 
growth signals, such as those resulting from the expression of the oncogenes Ras or Myc. 
These oncogenes stimulate the transcription and stabilization of the p14 protein, which binds 
to Mdm2 and inhibits its activity (Sherr and Weber 2000), thereby preventing p53 binding and 
degradation. 
 As a result of activation, numbers of genes have been identified as transcriptional 
targets of p53. These can be placed into a number of classes according to their functions.  
Protein products of these genes control processes such as cell cycle arrest, DNA repair and in 
many cases they even cause the programmed death (apoptosis) in response to genotoxic 
damage as well as oncogene activity to protect the organism (Vousden and Lu 2002; Lee and 
Schmitt 2003). The p53 protein therefore provides a critical brake on tumor development, 
explaining why it is so often mutated in cancers. 
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1.3.1 The p53 apoptotic pathway  
In normal cells DNA damage triggered by anthracyclines and ionizing radiation is 
detected by the protein product of the ATM, transducted towards cell cycle arrest and/or 
apoptosis through the p53 pathway (Figure 1). 
A single dsDNA break is sufficient for ATM activation. ATM activates Chk2 by 
phosphorylating amino acid Thr68 (Matsuoka, Rotman et al. 2000). Phosphorylation of Thr68 
leads to autophosphorylation of Thr383 and Thr387 in the Chk2 kinase domain (Lee and 
Chung 2001). ATM can also phosphorylate p53 directly at Ser15 (Delia, Mizutani et al. 2000) 
a site close to the interaction region of Mdm2. Phosphorylation of Ser15 will obstruct binding 
of Mdm2 and increase the stability of p53 (Delia, Mizutani et al. 2000). ATM can also 
phosphorylate Mdm2 directly on Ser395 to decrease its affinity to p53 (Khosravi, Maya et al. 
1999).  
 
ATM
MDM2
CHK2
ARFp14
p53
Apoptosis
Repair
Cell cycle arrestp21B
p21
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic illustration of p53 apoptotic pathway following DNA damage. ATM activates Chk2 by 
phosphorylation which in turn phosphorylates p53. Arrows indicate activation/induction while butt ends indicate 
inhibition. 
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The CHEK2 gene is located on chromosome 22q12.1. The gene contains 14 exons, 
and encodes a protein of 543 amino acids. The protein Chk2, a serine/threonine kinase, plays 
an important role in double strand break responses leading to cell cycle checkpoint arrest, 
apoptosis and DNA repair, as mentioned above. The Chk2 protein (Figure 2) consists of three 
distinct functional domains. The most amino terminal of these are the SQ/TQ cluster domain 
(aa 19 – 69), which contains Thr68, the site phosphorylated in response to DNA damage by 
the upstream kinase, ATM, as mentioned above. Downstream of the SQ/TQ domain the 
forkhead associated domain (aa 115 – 165) is located, which function in trans to modulate 
protein interactions and in cis to affect other functional domains within the protein itself. The 
kinase domain (aa 225 – 490) is located almost on the entire C-terminal half of Chk2 (Ahn, 
Urist et al. 2004). On DNA damage signal, oligomerization of Chk2 is activated by 
phosphorylation of Thr68, which serves as a ligand for the forkhead-associated domain of 
another Chk2 molecule (Ahn, Li et al. 2002). This allows autophosphorylation of Thr383 and 
Thr387 resulting in the release of active Chk2 monomers, which function in DNA damage 
induced cellular responses by activating p53 by phosphorylating p53 at Ser20 (Khanna, Lavin 
et al. 2001). These phosphorylation events disrupt the binding interface between Mdm2 and 
p53, increasing the p53 population. 
 
 
 
 
 
 
 
 
 
 
 
KINASE
225-490
aa1 aa543
P
ATM
P P
T383 T387
SQ/TQ
19-69
FHA
115-165
T68
 
Figure 2: Chk2 structure is shown schematically with the functional domains. Following DNA damage ATM 
activates Chk2 by phosphorylating Thr68. 
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 The TP53 gene, located on chromosome 17q13.1, contains 11 exons and encodes a 
protein of 393 amino acids with the central region harboring the DNA binding domain (Figure 
3).  Activation of p53 by Chk2 phosphorylating Ser20 in response to DNA damage result in 
an increase in the levels of p53 protein due to reduced Mdm2 dependent proteolytic 
degradation, and increased affinity of p53 for sequence specific DNA binding activity.  
As mentioned above, an increasing number of genes are being identified as 
transcriptional targets of p53 (Vogelstein, Lane et al. 2000; Kannan, Amariglio et al. 2001). 
Stabilized p53 regulates transcription of several downstream factors, including members of  
KIP family (p21/p27/p57) (Bates and Vousden 1999) (described below), GADD45,  14-3-3-
Sigma genes leading to cell cycle arrest and repair (el-Deiry 1998). There are several potential 
mediators of p53 induced apoptosis, mediators like Bax, p53AIP1, Noxa proteins are located 
in mitochondria and when activated/over-expressed induce apoptosis (el-Deiry 1998). Other 
potential mediators of p53 induced apoptosis include TNF (tumor necrosis factor) receptor 
and FAS (Lin, Ma et al. 2000). p53 can also cause cell death by directly stimulating 
mitochondria to produce an excess of highly toxic reactive oxygen species (Vogelstein, Lane 
et al. 2000). Although most of effects of p53 are ascribed to its function as transcription 
factor, several reports have suggested that p53 can also induce apoptosis in transcription 
independent mechanisms (reviewed by (Chipuk and Green 2003). 
ATM
CHK2
Figure 3: p53 structure is shown schematically with the functional domains. The p53 contains the TAD (trans 
activation domain) domain, which is responsible for activating target genes, a PRD (Proline rich domain) 
domain, and the DBD (DNA-binding domain) which consists of a variety of structural motifs including L2/L3.  
aa1 S15 S20
P P
aa393CTD
360-393
PRD
61-93
L2
163-195
L3
236-251 NLS
TET
325-356
aa1-44 aa102-292
TAD DBD
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1.4  Kinase Inhibitor Protein (KIP Family) 
Progression through the cell cycle is governed by cyclin-dependent kinases (CDKs). 
Activation and deactivation of these kinases leads to proper phosphorylation of their 
downstream targets, pRB (retinoblastoma protein) which inhibits cell cycle progression 
through interacting transcription factors such as E2F1. When pRB becomes phosphorylated 
by CDKs, E2F1 is released and stimulates proliferation. CDK inhibitors have been suggested 
to be indirectly involved in apoptosis through regulation of CDKs. Improper regulation of 
CDK can send erroneous signals for cell division and cell cycle arrest. Two families of CDK 
inhibitors, INK4 (inhibitor of CDK4) and KIP (kinase inhibitor family) negatively regulate 
CDK activities and mediate cell cycle arrest following growth inhibitory signals (Tsihlias, 
Kapusta et al. 1999). 
The INK4 family of proteins, composed of p15 (INK4B), p16 (INK4A), p18 (INK4C) 
and p19 (INK4D) inhibits specifically cyclin D-associated kinases (Parry, Bates et al. 1995). 
The KIP family of proteins, composed of p21 (WAF1, CIP1), p27 (KIP1) and p57 (KIP2), 
binds and inhibits cyclin E/CDK2, cyclin A/CDK2, and cyclin B/CDK1 complexes (Figure 4) 
(Sherr and Roberts 1999). All three members of the KIP family contain characteristic motifs 
in their N-terminal domains, enabling them to bind both the cyclin and the CDK subunits of 
the active cyclin/CDK complexes (Warbrick, Lane et al. 1995; Russo, Jeffrey et al. 1996). 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
P
RB
E2F
E2F
P
RB
P
P
Cyclin D
CDK4/6
p21
DNA-synthesis
Cyclin A/E
CDK2
p27
p57
Cyclin B
CDK1
p21
G2
S
G1
p21
Figure 4: Schematic illustration of KIP family influence on cell cycle at several stages. Arrow indicates 
activation/induction while butt ends indicate inhibition. 
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Several factors affect p21 levels and its activity in the cell. p21 is synthesized during 
the p53 dependent G1 cell cycle arrest, where its primary function is cell cycle arrest 
(Waldman, Kinzler et al. 1995). However, p21 has been reported to express both anti- or pro-
apoptotic functions (el-Deiry, Harper et al. 1994), depending on the experimental conditions, 
p21 is capable of binding and inhibit the kinase activity of the complexes of cyclin A or E and 
CDK2 during G1. Its repression of G1/S transition is considered to be its main role in cell 
cycle control. This leads to activation of the E2F family of transcription factors by 
phosphorylation of the pRB, promoting release of E2F1 from the pocket domain (Harbour, 
Luo et al. 1999). Further downstream effects include RB-mediated apoptosis. p21 can also 
bind and inhibit cyclin B/CDK1 during G2 cell cycle arrest (Caldon, Daly et al. 2006). 
p21B is a recently discovered protein translated from an alternative transcript of the 
CDKN1A gene. Expression of p21B is transcribed by an independent promoter, and the 
processed transcript consists of a short first exon (Exon IB) spliced to a longer exon (Exon 
IIB) that comprises half of intron II, exon II, intron III and exon III harboring the p21B coding 
region (Figure 5). p21 and p21B do not share any amino acid sequence (Nozell and Chen 
2002). As p21B was recently described, and the only study which have addressed the 
functional aspect of p21B indicated that over-expression of p21B leads to apoptosis through 
the mitochondrial pathway (Figure 1) (Nozell and Chen 2002). The results from the same 
work also indicated that p21B expression is induced by p53 through p53 binding. However, 
so far, these data are not confirmed by other groups. 
 
 
 
 
 
 
 
 
 
 
 
p21 gene
p21 promoter
Exon 1
p21B promoter
p21B mRNA transcript
Exon 1B
Exon IIB
P21 mRNA transcript Exon 1
Exon 1B
Exon II Exon III
Exon IIB
Exon II Exon III
Coding region Coding region
Coding region
Figure 5: Schematic representation of the CDKN1A gene with p21 and p21B transcripts.
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 p27 is found to execute its function by inhibiting the cyclin E/CDK2  complex (Figure 
4) (Tsihlias, Kapusta et al. 1999). The importance of p27 in regulating the cell cycle is further 
supported by the fact that mice lacking the encoding p27 have rapid growth arrest (Kiyokawa, 
Kineman et al. 1996). Therefore it appears more and more likely that p27 is involved as a 
tumor suppressor gene and triggers apoptosis (Katayose, Kim et al. 1997). Moreover p27 
inhibits angiogenesis and migration (Goukassian, Diez-Juan et al. 2001) and therefore it may 
also inhibit distant metastasis.  
p57, another member of the KIP family, contains three structural domains: an N-
terminal region bearing homology with p21 and p27, a central proline-rich domain, and a C-
terminal region (QT) domain shared with p27 (Lee, Reynisdottir et al. 1995). The tumor 
suppressor p57 functions as a negative regulator of cellular proliferation (Lee, Reynisdottir et 
al. 1995). It is reported that ablation of the p57 results in increased apoptosis and plays a 
major role in embryonic development where its loss leads to developmental disorder (Yan, 
Frisen et al. 1997). 
It seems clear that the main function of the KIP family is to negatively regulate the 
activity of CDKs. However, it seems like that p21 have some additional roles which makes 
the overall picture more complex. Some data indicate that p21’s interaction with the cyclin 
D/CDK4 complex (Figure 4) was not of an inhibitory kind, but rather an interaction required 
for proper assembly of the functional active kinase complex, which will promote the cell 
progression through G1 (LaBaer, Garrett et al. 1997; Cheng, Olivier et al. 1999). This raises 
the question of why p21 inhibits cyclin E/CDK2 but stabilizes cyclin D/CDK4 when 
downstream target for both these kinases is pRB. 
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1.5 Prognostic and predictive value of gene mutations in breast cancer 
  Several studies have investigated the prognostic (survival or disease free survival) and 
predictive (factors associated with sensitivity or resistance to a specific treatment) value of 
different genetic alterations in patients with tumor response to treatment in various cancers. 
However, different clinical and methodological settings have been used and the results have 
often been heterogeneous and conflicting (Lonning 2007; Lonning, Knappskog et al. 2007). 
 
 
1.5.1  Prognostic and predictive value of TP53 mutations in breast cancer 
A large number of studies have evaluated the prognostic and predictive role of the 
TP53 alterations in cancer yielding conflicting results. Mainly two different methodologies 
have been used to assess TP53 alterations: DNA sequencing and IHC. As the majority of 
TP53 point mutations leads to the synthesis of a stable, non-functional and non-degradable 
protein that accumulates in tumor cells, increased protein expression has been used as a 
surrogate parameter for TP53 mutations. The correlation between p53 protein accumulation 
measured by IHC and TP53 mutations detected by sequencing is, however, less than 75% in 
breast cancer (Sjogren, Inganas et al. 1996; Geisler, Lonning et al. 2001). One of the reasons 
for this is that not all mutations yield a stable protein and some mutations result in protein 
truncation and are thus not detected by IHC. Non-mutated p53 protein may also accumulate in 
some cells as a result of response to DNA damage, giving a positive IHC result. Studies that 
have used sequencing to detect mutations all showed a strong association to prediction 
whereas most studies using IHC failed to detect such an strong association (Soussi and 
Beroud 2001).  
It has been reported that patients with mutations effecting or disrupting the zink 
binding domain  L2 (codon 163-195) and L3 (236 – 251) have worse prognosis than patients 
with mutations outside L2/L3 domains (Borresen, Andersen et al. 1995). Mutations affecting 
amino acids directly involved in DNA binding (Figure 3), many of these residing in the L2/L3 
domain, were related with the worst prognosis (Berns, Foekens et al. 2000) and displayed 
aggressive phenotype with a short survival (Alsner, Yilmaz et al. 2000). Mutations causing 
loss of the native protein structure have also been associated with poor prognosis (Powell, 
Soong et al. 2000). 
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There are strong biological reasons for investigating whether mutations in the TP53 
gene are predictors of response to chemotherapy, since TP53 is involved in control of the cell 
cycle, in repair after DNA damage, and in apoptosis. Several studies have reported that for 
locally advanced breast cancers treated with different anthracyclins in a neo-adjuvant setting, 
there was strong evidence that TP53 mutations in general and especially mutations disrupting 
the zink binding domains (L2/L3) correlated with primary resistance (Aas, Borresen et al. 
1996; Kandioler-Eckersberger, Ludwig et al. 2000; Geisler, Lonning et al. 2001; Geisler, 
Borresen-Dale et al. 2003). Berns and collaborators (Berns, Foekens et al. 2000) studied 
whether TP53 mutations can predict response to tamoxifen chemotherapy in patients with 
advanced disease. A total of 243 patients were included in the study. Patients with TP53 
mutations in codons that directly affected DNA binding or mutations within the zink binding 
domain L3 showed the lowest response to tamoxifen. Another study found that adjuvant 
therapy, with tamoxifen along with radiotherapy was of less value for patients with TP53 
mutation (Bergh, Norberg et al. 1995). In another small study of advanced breast cancer 
patients treated with anthracyclines (35 patients) or paclitaxel (32 patients) in a neo-adjuvant 
setting, a strong correlation between lack of response and presence of a TP53 mutation was 
observed in the patients treated with anthracyclines but not in the paclitaxel treated group 
(Kandioler-Eckersberger, Ludwig et al. 2000).  
At least 14 different single nucleotide polymorphisms (SNP) have been reported in the 
TP53 gene, with Arg72Pro as the most common variant. Ethnic differences are observed for 
this SNP, the Arg72Arg variant  being more prevalent in Caucasians, whereas the Arg72Pro 
variant is more prevalent in Chinese and African-Americans (Beckman, Birgander et al. 
1994). Few studies have analyzed the impact of the Arg72Pro mutation on cancer risk, the 
results are conflicting and no clear consensus has been reached. For the impact on cancer 
outcome, one study on breast cancer patients showed that those carrying a Pro/Pro variant 
may be less sensitive to anthracyclines-based treatment than those with Pro/Arg or Arg/Arg 
and suggests that analysis of p53 codon 72 polymorphisms may provide a simple predictive 
marker for selecting the right breast cancer patients to anthracycline-based neo-adjuvant 
chemotherapy (Xu, Yao et al. 2005). This result, however, needs confirmation. 
All the data reported point to a significant clinical implication of TP53. However, 
there are no clear consensuses on the specific type of mutations carrying a worse prognosis or 
prediction, as different classifications of mutations have been used and the comparison of 
individual mutations was limited by a lack of statistical power. In addition, data clearly show 
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that the type of the mutation and its biological function should be considered in the analysis of 
the prognostic and predictive factor. 
1.5.2  Prognostic and predictive value of CHEK2 mutations in breast cancer 
A recurrent mutation in the CHEK2 gene, 1100delC, was first to be associated with 
family cancer (Meijers-Heijboer, van den Ouweland et al. 2002). Since then, numerous 
studies have documented the prevalence of this single founder mutation in various 
populations.  In terms of pathology, 1100delC tumors did not seem to be appreciably different 
from the mutation-negative tumors in 1479 women from the Netherlands treated for invasive 
breast cancer before the age of 50 years, the mutation 1100delC was identified in 3.7% of the 
patients (Schmidt, Tollenaar et al. 2007). However the women in the CHEK2 subgroup 
harbored a two-fold increased risk of developing breast cancer in that study. A prospective 
study of 9231 individuals from the Danish general population, observed for 34 years, 
suggested that 1100delC heterozygosity is associated with a three-fold risk of breast, prostate 
and colorectal cancer (Weischer, Bojesen et al. 2007). Other reports have also suggested that 
breast cancer patients with a 1100delC mutation have an increased risk of second breast 
cancer and have a worse long-term relapse-free survival rate (Meyer, Dork et al. 2007; 
Schmidt, Tollenaar et al. 2007). Several studies have reported germline CHEK2 mutations 
Arg117Gly or Ile157Thr not to be associated with hereditary breast cancer (Allinen, Huusko 
et al. 2001; Schutte, Seal et al. 2003). However, CHEK2 mutations are found at low incidence 
in human cancer in general, and the combination of lack of functional studies evaluating 
different mutations makes evaluation of CHEK2 mutations difficult. 
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1.5.3. Prognostic and predictive value of KIP family mutations in breast cancer 
Because of its central role in cell cycle control, p21 has been frequently studied. 
Several groups have addressed the potential role of p21 mutations and polymorphisms as risk 
factors for cancer development (Sjalander, Birgander et al. 1996; Facher, Becich et al. 1997; 
Chen, Wu et al. 2002). However, until now the only study exploring p21 mutation or 
polymorphism status in relation to response to chemotherapy treatment in breast or other type 
of cancers in vivo was conducted by us (Chrisanthar, Knappskog et al. 2007). In our study, 
totaling 521 breast cancer patients, no p21 mutations were observed. We identified three 
polymorphisms in addition to the earlier reported p21G251A polymorphism, which was found 
to be associated with locally advanced breast cancer (Staalesen, Knappskog et al. 2006). 
However, none of these polymorphisms predicted response to chemotherapy treatment. 
Galmarini et al. (Galmarini, Bouchet et al. 2006) found a T insertion in codon 104, resulting 
in truncation of the p21 protein, to be associated with a poor response to paclitaxel in 
noncancerous breast epithelial cells in vitro. However, this was linked to a single mutation 
only (the same mutation appearing in several drug resistant populations of a mammary cell 
line). 
 As only limited experimental information is available about the p21B, it is not clear 
whether or not this protein plays a role as a prognostic or predictive factor. Mutation 
screening in breast tumor samples has so far not revealed any high frequency of mutation in 
the coding region or promoter hypermethylation, indicating that p21B does not play an 
important role in breast cancer development (Staalesen, Leirvaag et al. 2004). Both studies 
revealed none of the polymorphisms in p21B so far identified to be associated with resistance 
to chemotherapy (Paper III). 
Reduced p27 expression has been shown to predict a poor prognosis in breast cancer 
(Catzavelos, Bhattacharya et al. 1997; Porter, Malone et al. 1997; Tan, Cady et al. 1997). 
However, until now there are no studies exploring p27 mutation or polymorphism status in 
relation to response to chemotherapy treatment or as a predictive factor in human cancers. 
Recently, we discovered the p27Val109Gly polymorphism not to be a factor predicting epirubicin 
or paclitaxel resistance in breast cancer (Paper II). 
Deletions within  the proline-alanine-rich region of the p57 are relatively common in 
human populations (Kondo, Matsuoka et al. 1996; Matsuoka, Thompson et al. 1996). p57 
germline deletions within the proline-alanine-rich region has been suggested to be associated 
with increased risk of a variety of cancers, including breast cancer (Tokino, Urano et al. 
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1996). In the same study the investigators found that a silent single-base pair substitution 
polymorphism in codon 185 (GCTGCC) was not associated with increased cancer risk. 
 
 
1.5.4 Prognostic and predictive value of functional pathways 
Finding that alterations in individual genes are associated with but not fully predictive 
to response to chemotherapy treatment has lead to increased focus on the probability of 
testing not only alterations in individual genes but rather, multiple genes in concert using 
methods such as microarrays.  
Microarrays have been used to explore the biology pattern of most tumor types. 
Several studies (Perou, Sorlie et al. 2000; Sorlie, Perou et al. 2001) showed that breast cancer 
may be classified on the basis of hierarchal analysis of gene expression patterns identified by 
microarray. The problem of using such patterns to select patients for therapy lies in the fact 
that we here, as for individual genes, lack useful clinical information associated with 
predictive value, even though several studies have reported gene expression patterns 
associated with sensitivity to different chemotherapy drugs (Chang, Wooten et al. 2003; 
Ayers, Symmans et al. 2004; Ma, Wang et al. 2004; Rouzier, Perou et al. 2005; Sorlie, Perou 
et al. 2006). However, none of these microarray patterns have come to clinical use for a 
couple of reasons. These patterns have been developed in studies enrolling a limited number 
of patients only or they consistently reported sensitivity as well as specificity predicting 
therapy outcome of  ~70-80%, which is below what should be required if a parameter is to be 
used to select patients for different therapies. In addition, microarray classification cannot be 
used prospectively to classify new tumors, as the dendograms of hierarchical clustering 
analysis are re-organized when a new sample is added (Chang, Hilsenbeck et al. 2005).  
 Each individual factor found to be associated with chemotherapy so far has been 
involved in specific biological processes, either processes involved in targets of the drug or 
associated with processes such as cell cycle arrest/DNA repair or apoptosis. Most of these 
gene products carry out their function in complex with other factors. They are activated by 
certain upstream factors and then activate downstream factors in functional pathways. 
Therefore, it is likely to postulate that inactivation of specific factors up- or downstream in the 
same pathways in a functional cascade, may lead to similar effects. 
A key problem applying to such a model is that for instance in the p53 apoptotic 
pathway, we lack exact knowledge about which specific factors are involved downstream of 
p53. Data from in vitro experiments, show that p53 activates several hundred genes (Kannan, 
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Amariglio et al. 2001; Yeoh, Ross et al. 2002). However, this represents a huge reduction in 
the number of candidate genes to explore compared with the use of general microarray. Thus, 
gene arrays including genes involved in certain biological pathways may be a way to advance. 
However, as each tumor will express different gene patterns (Lonning, Knappskog et al. 
2007) in respect to the genes involved in different pathways, we believe that microarrays gene 
expression data must be used in combination with other methods for gene alterations.
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1.6 Family Cancer Syndromes 
A family cancer syndrome is a phenotypical condition characterized by an abnormal 
high incidence and (in general) early diagnosis of one or several specific forms of cancer. The 
underlying genetic factors characterized so far, the hallmark of families with inherited cancer 
syndromes are germline mutations of central cell cycle, DNA repair and apoptosis regulating 
genes. Approximately 5-10% of all breast cancers are assumed to be inherited. The majority 
of these cancers are inherited in an autosomal dominant manner. There are many cancer 
predisposing genes and each one of these genes, has a specific variant of cancer associated 
with it (Nagy, Sweet et al. 2004). Normally, the term hereditary or familial cancer syndrome 
is used only for families with the following characteristics: More than two relatives with the 
same type of cancer on the same side of the family, diagnosis at early ages than what is 
typically seen for that cancer type and individuals with multiple primary cancers. However, 
these criteria can be different for different types of cancer. Because of differences in 
phenotypic variability, gender specific cancer risks and age related penetrance, many families 
with cancer predisposing genetic alterations may not fulfill these criteria. Also, with respect to 
the fact that cancer is relatively common in the western population, for some families with a 
high incidence of cancer cases which look like an inherited cancer syndrome, cancers may 
still occur by chance. In the following, the most important cancer predisposing genes are 
briefly described. 
The RB gene, located at chromosome 13, was the first gene identified in which a 
germline mutation was found to be associated with a particular cancer. A novel germline 
mutation in RB leads to development of familial and sporadic retinoblastoma tumors (Friend, 
Bernards et al. 1986). As mentioned above, the pRB acts as an inhibitor of the cell cycle 
progression stimulator E2F1. E2F1 is a key transcription factor in late G1 of cell cycle, 
regulating expression of genes needed to enter S-phase. Mutations in RB cause a high risk for 
early onset retinoblastoma. 
As mentioned above, BRCA1 and BRCA2 gene mutations are associated with an 
increased risk for breast and ovarian cancer. These genes have been shown to play a role in a 
multitude of cellular processes, including but not limited to DNA transcription, cell cycle 
regulation, DNA damage repair, and apoptosis (Jasin 2002; Somasundaram 2003). 
The CDKN2A gene encodes two cell cycle regulatory proteins, p16(INK4a) and 
p14(ARF). p16, which is a tumor suppressor, executes its function, as a specific inhibitor of 
the catalytic activity of cyclinD/CDK4 complexes (Serrano, Hannon et al. 1993). While 
 23
CDKN2A are the gene for which germline mutations frequently have been linked to hereditary 
cases of malignant melanoma, there are continued discussions about how the inactivation of 
p14 leads to malignant melanoma. Mutations in the locus, CDK4, are much rarer and have 
been linked to the melanoma in only three families worldwide. (Molven, Grimstvedt et al. 
2005; Helsing, Nymoen et al. 2008). Even though p16 and pRB are functionally linked, 
germline genetic alterations of these genes encoding these two proteins predispose to different 
malignancies, malignant melanoma and retinoblastoma, respectively. 
Common for the above mentioned genes are that when inactivated, a major increase in 
the risk of one major, or limited number of cancer forms, is observed. However, there are 
genes that when mutated, cause an increased risk for multiple cancer forms. Mutations in 
genes which cause syndromes like Li-Fraumeni (described below) severely increase the risk 
of breast cancer in addition to other forms of cancer.  
 
 
1.6.1 Li-Fraumeni Syndrome (LFS) 
Li-Fraumeni syndrome (LFS) is a rare autosomal dominant syndrome and was first 
described by Fredric Li and Joseph Fraumeni in 1969. LFS is characterized by a wide variety 
of cancer types seen in affected individuals. Li-fraumeni syndrome is diagnosed if the 
following three criteria are met: 1. The patient has been diagnosed with any bone or tissue 
sarcoma when younger than 45 years of age; 2. A first degree relative with any cancer under 
45 years of age; 3. Another first or second degree relative in the same linkage has been 
diagnosed with any cancer at an age below 45 or with a sarcoma diagnosed at any age. 
Typically, breast, brain, adrenocortical cancers, sarcomas and acute leukemia are diagnosed 
when younger than 45 years, but also other tumors (Li, Fraumeni et al. 1988). Having 
discovered families with a less severe cancer phenotype presented in the criteria for LFS, a 
somewhat milder definition of LFS, named the Li-Fraumeni like (LFL) syndrome has been 
defined with the following criteria: A proband with any childhood tumor or sarcoma, brain 
tumor or adrenocortical tumor under 45 years plus a first or second-degree relative with a 
typical LFS cancer at any age and another first or second-degree relative with any cancer 
under the age of 60 (Birch, Hartley et al. 1994). 
The underlying genetic defect in many Li-fraumeni families is believed to be a 
germline mutation in the TP53 gene as first described by Malkin et al. (Malkin, Li et al. 
1990). TP53, a tumor suppressor gene, has proven to be one of the most important genes 
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involved in the development of cancer. In addition, to the gene’s role in non-inherited 
mutations in human tumors, it is also found as germline mutation. Germline mutations in the 
TP53 gene have been observed in approximately 63% of the (LFS) and 27% of LFS like 
families, respectively (Eng, Schneider et al. 1997) and with mutations affecting the DNA-
binding domain of the TP53 gene have generally more cancers and at younger ages than 
families with mutation not affecting DNA-binding domain or with no germline TP53 
mutation (Birch, Blair et al. 1998). 
CHEK2 is a tumor suppressor gene that, when mutated, produces effects similar to 
those of p53 mutations and are involved in the development of several human cancers. 
CHEK2 germline mutations have been found to confer an increased risk of some cancer and 
are identified in Li-Fraumeni syndrome families lacking mutations in TP53 (Bell, Varley et al. 
1999). Bell and coworkers found three distinct CHEK2 alterations (1100delC, Ile157Thr and 
1422delT) in three of the families in total out of four LFS and 18 LFL families. However, 
there is increased discussion and evidence about the fact that germline mutation in CHEK2 
does not cause Li-Fraumeni Syndrome. Nayanta et al. (Sodha, Bullock et al. 2002) showed 
that one of the mutations 1422delT, is a variant in a homologous fragment of  the gene present 
in Chromosome 15. The second mutation Ile157Thr, has been reported to be a polymorphism 
in the Finnish population (Allinen, Huusko et al. 2001) while the mutation 1100delC, leads to 
truncated protein and is therefore likely to be pathogenic. This raise the intriguing question 
about CHEK2 mutations related to LFS.  
On the basis of that 1100delC is a predominant founder mutation in CHEK2 which is 
carried by 0.7% of the Northern European population. In contrast, the LFS is believed to 
affect only one in 20 000 births or approximately 100 times less (Lalloo, Varley et al. 2006). 
Further, a detailed analysis of 67 CHEK2 families (Thompson, Seal et al. 2006) failed to 
identify an increased risk of cancer for any site other than breast cancer, in a resent paper 
Evans and colleagues (Evans, Birch et al. 2008) have concluded that CHEK2 mutations are 
not associated with the cancer types seen in the LFS or LFL. 
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2 PREVIOUS WORK AND AIMS OF THE PRESENT STUDY 
 
In breast cancer, only a minority of the patients fully benefit from the different 
chemotherapy regimens in use, considering that many patients will fail to respond and that 
chemotherapy has toxic side effects. Identification of markers that could predict response to 
certain chemotherapy schedules would be of great value. Despite this, the number of studies 
designed specifically to explore the mechanism of drug resistance in vivo is low compared to 
the high number of studies done in vitro and clinical trials assessing responses in general. 
Even though microarray data provide large amounts of information revealing gene 
expression in single analysis, it is clear that such arrays may not identify every potential 
mechanism of gene inactivation. Alternative splicing, as well as single base mutation or even 
a deletion or a splice defect located downstream of the probing area would be missed. For 
single base substitutions within the area covered by the probe, the result is less predictable, as 
the transcript may not bind the probe at all, or in other cases it may still bind partly or 
completed and thus the substitutions may be overlooked. A resent paper (Michiels, Koscielny 
et al. 2005) have intriguing questions about the validity of several extensively published 
expressing profiling studies. Using a simple but insightful approach, these authors showed 
that in five of these seven studies on array expression the signatures perform no better than 
what could be expected for random variation or in more popular terms “tossing the coin”.  
Because not all mutations yield a stable protein and some mutations result in truncated 
protein and are thus not detected by IHC as well as the fact that wild type proteins may 
accumulate in some cells, the research activity of our team has focused on exploring 
mechanisms of chemoresistance in breast cancer by conventional sequencing of the coding 
region of candidate genes of functional pathways and especially exploring mutational and 
epigenetic alterations of genes involved in apoptosis and cell cycle arrest. Mutations in many 
of these genes are associated with hereditary disposition for cancer development, and findings 
by our group and others have shown that mutations in TP53 are associated with 
chemoresistance in breast (Kandioler-Eckersberger, Ludwig et al. 2000; Geisler, Lonning et 
al. 2001; Geisler, Borresen-Dale et al. 2003) but also hematological malignancies (Diccianni, 
Yu et al. 1994; Wattel, Preudhomme et al. 1994; Preudhomme, Dervite et al. 1995). Also, the 
pathways in which the products of these genes execute their function are important for the 
response to chemotherapy (Lonning 2004). 
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Previously, our group reported mutations in the zink-binding domains L2 (codons 163-
195) and L3 (codons 236-251) of p53 critical to DNA binding (Cho, Gorina et al. 1994) to be 
associated with, but not fully predictive for resistance to anthracycline (Geisler, Lonning et al. 
2001) or a mitomycin plus 5-fluorouracil (Geisler, Borresen-Dale et al. 2003) regimen. In that 
study, the finding that some tumors harboring wild type TP53 and be resistant to 
anthracycline therapy made us postulate that other genes involved in the p53 pathway could 
be mutated in these tumors. In addition, the finding that some patients are sensitive to therapy 
despite their TP53 mutation made us postulate that redundant mechanisms may be involved in 
initiating apoptosis in response to anthracycline therapy. 
The primary goal of the present study was to investigate and possibly identify the 
cause of therapy failure in patients with non-responding tumors. The patients analyzed in this 
work are from two separate treatment regimes, where patients were treated with either 
epirubicin (n = 109) or paclitaxel (n = 114) monotherapy. The reason for randomizing patients 
according to protocol was not to compare response between the two therapeutic options but to 
achieve balance between the two arms with respect to patient selection in as much as the 
protocol endpoint was to explore potential mechanisms of drug resistance to the regimens. 
Biopsies of the patients were collected neo-adjuvant (before treatment) to explore molecular 
parameters predicting response to epirubicin and paclitaxel monotherapy by analyzing for 
mutations in TP53, CHEK2 and other factors up/downstream of p53 along the entire coding 
region of these genes and not only in the “hotspot” areas. In addition, analyzing for mutations 
in genes involved in the cell cycle arrest as the alternative factors involved in resistance to 
chemotherapy. 
In case CHEK2 mutations are found to be germline, explore cancer distribution among 
relatives harboring the mutation in view of the continued debate about the cancer spectrum 
(LFS/LFL) associated with mutation in this gene in an unselected breast cancer cohort 
(unselected for family history). 
Furthermore, to evaluate the biochemical functions of the different mutant variants 
corresponding to previously mutations in the CHEK2 gene associated with resistance to 
chemotherapy. 
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3 SUMMARY OF PAPERS 
The results presented in this thesis have provided new insight with respect to 
functional pathways associated with chemoresistance in breast cancer in vivo and insight in 
family cancer incidence in relation to CHEK2 germline mutations. 
Paper I 
Previously, our group reported mutations affecting the L2/L3 domains of TP53 to 
predict resistance to a doxorubicin low dose (14 mg/m2) weekly regimen and to mitomycin 
combined with 5-fluorouracil in breast cancer. However, while mutations affecting the L2/L3 
domains of TP53 were associated with drug resistance, some tumors were found to be therapy 
resistant despite harboring wild type TP53. 
 In this study we explored alterations in the TP53 gene with respect to resistance to a regular 
dose epirubicin regimen in patients with primary, locally advanced breast cancer. Further to 
identify critical mechanisms activating p53 in response to DNA damage in breast cancer. To 
do so, we analyzed for inactivating mutations in the p53 activation genes CHEK2 and 
p14(ARF) as potential causes of drug resistance in tumor harboring wild type TP53. When 
mutations are detected evaluate the in vitro function of potential Chk2 and p14 protein mutant 
variants corresponding to identified mutations in the CHEK2 and p14(ARF) genes. In 
addition, when CHEK2 or p14(ARF) mutations were found to be germline, explore the 
incidence of different cancer distribution among relatives.  
Snap-frozen biopsies were collected from 109 patients with locally advanced breast 
cancer prior to treatment with epirubicin (90 mg/m2) administered at 3 weekly intervals as 
preoperative therapy. Each sample was investigated for TP53, CHEK2 and p14(ARF)
mutations with complete sequencing of the coding region. In addition, p14(ARF) was 
analyzed for promoter methylation. 
 Mutations in the TP53 gene were associated with lack of response to epirubicin for all 
mutations and especially for those affecting loop domains L2/L3 of the p53 protein. No 
statistically significant correlation between TP53 LOH and response to therapy was found. 
CHEK2 mutations were for the first time associated with lack of response (p = 0.0026). 
Notably, CHEK2 mutations associated with therapy resistance were found to abrogate Chk2 
protein dimerization and kinase activity in vitro. The occurrence of mutations affecting 
CHEK2 and/or TP53 strongly predicted therapy resistance, in particular when TP53 mutations 
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were restricted to those affecting the L2/L3 domains of p53. The phenotypes of the two 
families harboring the CHEK2 mutation Arg95Ter expressed increased incidence of different 
cancers, but in a manner not typical for the Li-Fraumeni or the Li-Fraumeni-like syndromes. 
No mutation or promoter methylation in p14(ARF) were detected. 
This study, (one of the largest studies performed to date) revealed a significant 
association between lack of response to epirubicin in vivo and mutations in the TP53 gene, 
particularly those affecting the L2/L3 domains of the p53 protein for the patients treated with 
epirubicin at regular doses. Most importantly, our finding that mutations in the CHEK2 gene 
abrogating dimerization and kinase activity were associated with drug resistance, confirms 
activation of p53 through phosphorylation by Chk2 to be a key event executing breast cancer 
response to anthracycline treatment in vivo.  
To our knowledge, this is the first study that directly relates response to epirubicin 
chemotherapy to CHEK2 alterations in human cancers. Moreover, it is the first study 
documenting mutations in two genes acting direct up/down-stream to each other to cause 
therapy failure, documenting not only the importance of a single gene but the role of a 
functional cascade.  The tumor suppressor gene CHEK2, when mutated, produces effects 
similar to those of TP53 mutations. The evidence suggests that it is part of the same functional 
pathway for controlling cell growth and replication. 
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Paper II 
The finding of patients treated with epirubicin contains wild type TP53 and CHEK2 
and not responding to treatment (Paper I) and mutated tumors responding to treatment 
suggested that additional pathway may be involved in initiating apoptosis in response to 
chemotherapy in breast cancer. 
Thus, to this end we have searched for alterations in other genes, involved in growth 
arrest/cell cycle control to explain this observation. 
p27 expression detected by immunostaining has previously been associated with 
prognosis in breast cancer.  In contrast to data on prognostication, we are not aware of any 
studies evaluating a potential role of p27 with respect to drug resistance. Here, we report on 
the p27 status with respect to mutations effecting the coding domains and distribution of a 
well defined polymorphism with respect to drug resistance. Also, we analyzed for a loss of 
heterozygosity in relevant samples. A total of 223 patients were equally divided (according to 
randomization) between paclitaxel and epirubicin monotherapy for primary/locally advanced 
breast cancers. 
Our findings are negative in the way that we discovered no mutations affecting the p27 
gene and we did not find any statistically significant association between presence of the 
polymorphism Val109Gly and drug sensitivity.  
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Paper III 
In Paper III, we reported the identification of a novel p21BG128T polymorphism in our 
tumor samples, in addition to the previously reported p21BT35C. Both polymorphism variants 
were found to be equally distributed not only among breast cancer and non-breast cancer 
individuals but also between different subgroups of breast cancer. Finding that mutations in 
p21B coding sequence are rare, as we detected only one mutation among 521 tumor samples 
analyzed, indicates that the protein product of this transcript does not play a key role in 
carcinogenesis of breast cancer or in relation to chemotherapy. However, based on its 
proposed function in apoptosis, it may well be that inactivation of other genes involved in the 
same pathway may be a mechanism causing resistance to chemotherapy in human breast 
cancer. Our studies on breast cancer do not exclude that p21B may be of importance for 
malignancies other than breast cancer.
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4 DISCUSSION 
During the last few years a number of possible mechanisms of resistance against 
chemotherapy have been proposed. While these have been evaluated under in vitro 
conditions, data on their clinical relevance are lacking. Even though there are some in vivo 
studies (Hamilton and Piccart 2000; Bertheau, Plassa et al. 2002) focusing on resistance to 
chemotherapy, these are not directly comparable, making a direct evaluation of possible 
mechanisms of resistance to individual drugs difficult. In addition, previously research in vivo 
has often been investigated single genes that can be used as predictive markers, while its 
important to identify these individual genes, a broader understanding of the biological process 
has been missing. This study has taken a step further to gaining insight into biologically 
pathways involved in resistance to chemotherapy in breast cancer. 
Our first paper (Paper I) is to our knowledge one of the largest studies thus far directly 
relating response to chemotherapy to TP53 mutations in breast cancer patients. The study 
verifies our previous findings (Geisler, Lonning et al. 2001; Geisler, Borresen-Dale et al. 
2003) regarding the predictive value of TP53 mutations as a whole and mutations affecting or 
disrupting the L2 and/or L3 domains of the p53 protein with respect to primary resistance to 
anthracycline (epirubicin) therapy “normal dose” (90 mg/m2) administered at 3 weekly 
intervals in breast cancer, contrasting to primary treatment consisted of weekly doxorubicin 
“low dose” (14 mg/m2) (Geisler, Lonning et al. 2001) and receiving combination 
chemotherapy with 5-fluorouracil (1000 mg/m2 on days 1 and 2) and mitomycin (6 mg/m2 on 
day 2), administered every 3 weeks (Geisler, Borresen-Dale et al. 2003). 
As experimental evidence suggests a key role for p53 is apoptosis in response to 
genotoxic agents (Lowe, Ruley et al. 1993; Lowe, Bodis et al. 1994). We defined the p53 
apoptotic pathway as follows: Epirubicin will lead to DNA damage in the cell, DNA damage 
activates ATM, ATM activates Chk2, Chk2 activates p53 by phosphorylation and activation 
of p53 leads to transcription of downstream genes which will lead to that cell can induce 
apoptosis. A key part of this model is that there are no alternative mechanisms. Thus all 
proteins are targets for mutations that lead to therapy failure. No single protein may substitute 
for a single inactivated protein in the p53 apoptotic pathway. There is however the finding 
that some patients treated with epirubicin contain TP53 mutations affecting the L2/L3 
domains and respond to treatment suggests that redundant pathway may be involved to 
compensate for the entire p53 apoptotic pathway (Lonning 2003; Lonning 2004). Tumors 
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being sensitive to therapy despite their TP53 mutation in the L2/L3 domains may have the 
redundant pathway intact, while tumors being TP53 mutated and resistant have this redundant 
pathway inactivated. Tumors that are resistant to therapy despite expressing wild type TP53 
may have a gene upstream or downstream of TP53 inactivated, in addition to inactivation of 
the redundant pathway. Postulating that these tumors may harbor genetic disturbances in 
genes playing a key role in the p53 pathway, we here sequenced TP53 along with CHEK2 and 
p14(ARF), the latter two known to play a critical role as p53 activators. 
Our findings have two major implications. First, we confirm that mutations in genes 
encoding proteins located within the same functional pathway may substitute for each other 
with respect to drug sensitivity, revealing for the first time a functional pathway critical to 
chemotherapy response in vivo. Second, this study is also the first reporting an association 
between CHEK2 mutations and therapy resistance in human cancers. Further, the 
identification of mutations in the CHEK2 but not in the p14(ARF) gene in resistant tumors 
suggests that Chk2 mediated phosphorylation of p53 is a critical event in executing anti-tumor 
effect as a response to DNA damaging agents in breast cancer. This adds to our understanding 
not only the function of p53 but Chk2 as well. The tumor suppressor gene CHEK2, when 
mutated, produces effects similar to those of TP53 mutations. The evidence suggests that it is 
part of the same pathway for controlling cell growth and replication. Further, it shows that 
p53 status alone cannot determine if the p53 pathway is intact and verify our hypothesis that 
tumors can have alterations in other components of the p53 apoptotic pathway even though 
p53 itself is normal. 
Even though mutations often are associated with loss of function, mutations in the 
TP53 gene have different biological effects (Di Como and Prives 1998; Flaman, Robert et al. 
1998; Monti, Campomenosi et al. 2002). Some mutated p53 proteins still bind to DNA with 
variable efficiency (Rolley, Butcher et al. 1995), while other mutant proteins may perform a 
dominant-negative effects on normal p53 or other upstream or downstream regulators (Chene 
1998). Even though these biological effects have been observed in vitro, their importance of 
the mechanisms to chemoresistance in vivo is incompletely understood. Our in vivo data 
indicate that mutations in functional domains may be of particular importance predicting 
resistance to epirubicin therapy. Grouping the mutants based on functional status will further 
improve the predictive value of certain TP53 and CHEK2 mutations.  
The results of Varley et al. (Varley, McGown et al. 1995) and our study demonstrate 
the importance of looking for mutations along the whole gene as our studies have shown that 
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point mutations in other domains than hot-spot locations of p53 or Chk2 can be functionally 
disruptive.  
Taken together, our in vivo, in vitro and family history data strongly suggest that the 
novel CHEK2 mutations identified in the present study (Arg95Ter) will affect Chk2 function
in vivo, contribute to cancer development and chemoresistance to anthracyclines in the tumors 
carrying this variant. In vivo, in vitro, and family pedigree of variant Ile364Thr behaved 
almost like the wild type Chk2, and this alteration alone may not be a disease-causing or 
resistance causing mutation, although the alteration may affect associations with other 
proteins. 
The role of Chk2 with respect to cancer family syndromes has been controversial. 
Following a report of a Li-Fraumeni family harboring a germline CHEK2 mutation (Bell, 
Varley et al. 1999), current opinion is that the most frequently observed mutation del1100C as 
well as the more infrequent I157T and the rare R117G point mutation may cause syndromes 
of moderately increased risk of breast as well as colorectal cancers (Meijers-Heijboer, Wijnen 
et al. 2003; Kilpivaara, Vahteristo et al. 2004; Kilpivaara, Alhopuro et al. 2006; Sodha, 
Mantoni et al. 2006). Observing that CHEK2 germline mutations revealed different types of 
cancers in an unselected breast cancer cohort (unselected for family history) in their family, 
may indicate variable phenotypic expression in the families with CHEK2 mutations or yet 
other genes may account for the Li-Fraumeni and Li-Fraumeni like families. A resent report 
by Evans and colleague (Evans, Birch et al. 2008) verify our data and conclude that CHEK2 
mutations are not associated with the cancer types seen in the LFS or LFL and it is no longer 
reasonable to consider CHEK2 mutations to be a cause of LFS. 
As we suggested that mutations in CHEK2 might provide the same effect as mutations 
in TP53. However, one critical point questioning this hypothesis is the fact that CHEK2 
mutations do not account for LFS or LFL, like p53 mutations do. One plausible explanation 
for this is that cancer susceptibility and resistance to therapy are two different processes that 
might be caused by slightly different patterns of mutations. Even though mutation in CHEK2 
and TP53 cause resistance to anthracylines, they may have different aspect on cancer 
development. This view is supported by similar phenomenon in other functional cascades, for 
example, the RB-pathway. Even though, pRB, cdk4 and p16 are functionally linked and 
mutations are reported to have the same effect on cell cycle progression, however, germline 
genetic alterations of these genes predispose to very different malignancies, retinoblastoma 
and malignant melanoma, respectively. However, our family history data are consistent with 
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the hypothesis that CHEK2 is a multi organ cancer susceptibility gene that acts in synergy 
with other genes or factors to cause cancer. 
In Paper II and paper III we investigated for mutations in genes involved in cell cycle 
arrest as cause and effects for chemoresistance since it is known that p53 has two separate 
roles in the responsiveness of cells to anticancer agents, apoptosis and cell cycle arrest (Bunz, 
Hwang et al. 1999). Further, a critical role of the p53 response to DNA damage is the CDK 
inhibitor p21 (Harper, Adami et al. 1993). Since p21 and p21B are downstream genes 
transcriptionally regulated by p53, and linked to the key cellular events growth arrest and 
apoptosis, respectively, alterations affecting the function of these transcripts may potentially 
influence the function of the p53 pathway and as our previous study showed that disturbances 
in p21 function are unlikely to play a major role in chemotherapy resistance in breast cancer 
in vivo  (Chrisanthar, Knappskog et al. 2007), to this end we have searched for alterations in 
other members of KIP family. The very low prevalence of p21B and p27 mutations together 
with the observation that none of the identified polymorphisms correlated to breast cancer 
therapy indicates that these genes are unlikely to play a major role in chemotherapy 
resistance.  
However, it may well be that these genes are disturbed by other mechanisms, or 
disturbance of other genes involved in the same pathway may be a mechanism causing 
chemoresistance in human breast cancer.  
That both polymorphisms in p21B (T35C and G128T) (Paper III) were equally 
distributed among breast cancer and non-breast cancer individuals and also between different 
subgroups of breast cancer, indicates that either p21B does not play an important role in 
breast cancer development.  
  These findings should have significant impact on future studies to identify potential 
factors involved in TP53-dependent drug resistance in vivo aiming at improved 
diagnostification and therapy. 
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5 FUTURE PERSPECTIVES 
 
The data described above provide an insight into the biology of the chemoresistance in
vivo, but reveal the need for further studies of this type to provide conclusive valuable 
information for future use in the clinic. 
The finding that some patients treated with epirubicin carry TP53 mutations affecting 
the L2/L3 domains and CHEK2 mutations respond to treatment suggests that either the 
mutants are not functionally inactivated or redundant mechanisms may be involved in 
initiating apoptosis in response to chemotherapy in breast cancer. Finding that other pathways 
must be able to compensate for the entire apoptotic p53 pathway, either in response to DNA 
damage, or through other effects the chemotherapy may have on cells leads to search for 
genetic and epigenetic alterations in upstream and downstream genes and also other pathways 
should be investigated. The question is; what may be the alternative pathway in patients 
harboring TP53 and/or CHEK2 mutations that respond to epirubicin treatment? Pathways to 
be examined on the basis of biological processes either they represent the target for drug or 
involved in processes such as growth arrest, apoptosis, or DNA repair should be a target. 
Grouping the mutants based on functional status will further improve the predictive 
value of certain TP53 mutations.  
In addition, it would be important to look at genomic deletions and insertions (one or 
more entire exons) which are frequent causes of cancer by using high resolution methods like 
MLPA (Multiplex ligation-dependent probe amplification). 
While we found that mutations of both TP53 and CHEK2 can occur in the same breast 
tumor, it will be of interest to determine whether such mutations are more likely to occur in 
the same or alternative subsets of tumors and also what may be the order of such events 
during the progress of tumor development. Clarifying these issues should not only help to 
better understand the biology of the p53 apoptotic pathway, but also help develop better 
treatment for cancer patients. Further work is required to determine the role of the identified 
mutations in breast cancer as predictive factors. Experimental systems have to be developed 
to evaluate the biochemical functions of the different mutations associated with and resistance 
to chemotherapy and poor prognosis.  
Paclitaxel is one of the most effective anticancer drugs used in the clinic to treat a 
variety of solid tumors. Despite its increasing use, especially as chemotherapy, few in vivo 
data are currently available to shed light on the mechanism of drug resistance. Despite this, 
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analyzing potential factors involved in paclitaxel resistance would without question be of 
value. Biopsies obtained during neo-adjuvant paclitaxel treatment provide a valuable 
opportunity for the investigation of factors that may be used as predictors. 
Understanding chemoresistance will represent a great improvement in our attempts to 
cure not only breast cancer but also cancer in general. 
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